Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 3, 2014, Pages 433-444

  Gastaldi, Lucia ^a   Battaglia, Luigi ^a   Peira, Elena ^a   Chirio, Daniela ^a   Muntoni, Elisabetta ^a   Solazzi, Ilaria ^a   Gallarate, Marina ^a   Dosio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Active targeting; Bioavailability; Biodistribution; Blood brain barrier; Central nervous system; Solid lipid nanoparticles

Indexed keywords

DRUG VEHICLE; SOLID LIPID NANOPARTICLE; DRUG; LIPID; NANOPARTICLE;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CIRCULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; FIRST PASS EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARACELLULAR DIFFUSION; PARTICLE SIZE; PERMEABILITY BARRIER; PHYSICAL CHEMISTRY; RECEPTOR MEDIATED ENDOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; TRANSCELLULAR DIFFUSION; TRANSPORT AT THE CELLULAR LEVEL; ANIMAL; DRUG EFFECTS; METABOLISM; PROCEDURES;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84904251850     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.05.004     Document Type: Review

References (104)

1. A. Misra, S. Ganesh, A. Shahiwala, and S. Shah Drug delivery to the central nervous system: a review J. Pharm. Pharm. Sci. 6 2003 252 273
2. W.M. Pardridg Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today 7 2002 5 7
3. W.M. Pardridge Blood-brain barrier drug targeting: the future of brain drug development Mol. Intervent. 3 2003 90 105
4. P. Blasi, S. Glovagnoli, A. Schoubben, M. Ricci, and C. Rossi Solid lipid nanoparticles for targeted brain drug delivery Adv. Drug Deliv. Rev. 59 2007 454 477
5. M. Patel, E.B. Souto, and K.K. Singh Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles Expert Opin. Drug Deliv. 10 2013 889 905
6. M. Ricci, P. Blasi, S. Giovagnoli, and C. Rossi Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr. Med. Chem. 13 2006 1757 1775
7. B.V. Zlokovic The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 57 2008 178 201
8. S. Ohtsuki, and T. Terasaki Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development Pharm. Res. 24 2007 1745 1758
9. T. Yoshikawa, and W.M. Pardridge Delivery of peptides and proteins through the blood-brain barrier Adv. Drug Deliv. Rev. 46 2001 247 279
10. M.W. Smith, and M. Gumbleton Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies J. Drug Target. 14 2006 191 214
11. A. Tsuji, and I. Tamai Blood-brain barrier function of P-glycoprotein Adv. Drug Deliv. Rev. 25 1997 287 298
12. A.H. Schinkel P-glycoprotein, a gatekeeper in the blood-brain barrier Adv. Drug Deliv. Rev. 36 1999 179 194
13. W.M. Pardridge Crossing the blood-brain barrier: are we getting it right? Drug Discovery Today 6 2001 1 2
14. G.G. Grant, N.J. Abbott, and D. Janigro Understanding the physiology of the blood-brain barrier: in vitro models news News Physiol. Sci. 13 1998 287 293
15. Q.R. Smith Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system Pharm. Biotechnol. 8 1996 285 307
16. Y. Takasato, S.I. Rapoport, and Q.R. Smith An in situ brain perfusion technique to study cerebrovascular transport in the rat Am. J. Physiol. 247 1984 484 493
17. F.E. D'Amour, and D.L. Smith A method for the determining loss of pain sensation J. Pharmacol. Exp. Ther. 72 1941 74 78
18. L. Sun, Glioma - exploring its biology and practical relevance, in: Intechopen (Ed.), Animal Models of Glioma, Anirban Ghosh, 2011.
19. R.K.W. Schwarting, and J.P. Huston The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Prog. Neurobiol. 50 1996 275 331
20. G.J.R. Delcroix, E. Elisa Garbayo, L. Sindji, O. Thomas, C. Vanpouille-Box, P.C. Schiller, and C.N. Montero-MeneI The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats Biomaterials 32 2011 1560 1573
21. E. Garbayo, E. Ansorena, J.L. Lanciego, M.J. Blanco-Prieto, and M.S. Aymerich Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease Mov. Disord. 26 2011 1943 1947
22. L. Lecanu, and V. Papadopoulos Modeling Alzheimer's disease with non-transgenic rat models Alzheimer's Res. Ther. 5 2013
23. E.Z. Longa, P.R. Weinstein, S. Carlson, and R.R. Cummins Eversible middle cerebral artery occlusion without craniectomy in the rats Stroke 20 1989 84 91
24. E. Barbu, E. Molnàr, J. Tsibouklis, and D.C. Górecki The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier Expert Opin. Drug Deliv. 6 2009 553 565
25. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
26. M. Dekker, Colloidal Drug Delivery Systems, New York, 1994, pp. 219-342.
27. I.P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar Potential of solid lipid nanoparticles in brain targeting J. Controlled Release 127 2008 97 109
28. S.M. Moghimi, C.J.H. Porter, I.S. Muir, L. Illum, and S.S. Davis Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating Biochem. Biophys. Res. Commun. 177 1991 861 866
29. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B.I.B. Ipe, M.G. Bawendi, and J.V. Frangioni Renal clearance of nanoparticles Nat. Biotechnol. 25 2007 1165 1170
30. J. Kreuter, and S. Gelperina Use of nanoparticles for cerebral cancer Tumori 94 2008 271 277
31. L. Juillerat-Jeanneret The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov. Today 13 2008 1099 1106
32. M. Mazza, I.F. Uchegbu, and A.G. Schätzlein Cancer and the blood-brain barrier: 'Trojan horses' for courses? Br. J. Pharmacol. 155 2008 149 151
33. D. Karkan, C. Pfeifer, T.Z. Vitalis, G. Arthur, M. Ujiie, Q. Chen, S. Tsai, G. Koliatis, R. Gabathuler, and W.L. Jefferies A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier PLoS One 3 2008 1 14
34. T.M. Göppert, and R.H. Müller Plasma protein adsorption of Tween 80-and poloxamer 188-stabilized solid lipid nanoparticles J. Drug Target. 11 2003 225 231
35. S.D. Tröster, K.H. Wallis, R.H. Müller, and J. Jörg Kreuter Correlation of the surface hydrophobicity of 14C-poly(methyl methacrylate) nanoparticles to their body distribution J. Controlled Release 20 1992 247 260
36. J. Kreuter Application of nanoparticles for the delivery of drugs to the brain Int. Congr. Ser. 1277 2005 85 94
37. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Büchel, H. von Briesen, and J. Kreuter Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Controlled Release 137 2009 78 86
38. D.S. Miller, B. Bauer, and A.M.S. Hartz Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacol. Rev. 60 2008 196 209
39. L. Battaglia, and M. Gallarate Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery Expert Opin. Drug Deliv. 9 2012 497 508
40. B. Lasa-Saracibar, A. Estella-Hermoso de Mendoza, M. Guada, C. Dios-Vieitez, and M.J. Blanco-Prieto Lipid nanoparticles for cancer therapy: state of the art and future prospects Expert Opin. Drug Deliv. 2012 9 2012 1245 1261
41. R.H. Müller, K. Karsten Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
42. R.H. Muller, S. Maassen, H. Weyhers, and W. Mehnert Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407 J. Drug Target. 4 1996 161 170
43. A. zur Mühlen, C. Schwarz, and W. Mehner Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155
44. C. Freitas, and R.H. Müller Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions Int. J. Pharm. 168 1998 221 229
45. L. Di, E.H. Kerns, Y. Hong, and H. Chen Development and application of high throughput plasma stability assay for drug discovery Int. J. Pharm. 297 2005 110 119
46. C.S. Djuzenova, T. Güttler, S. Berger, and A.F.M. Katzer Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment Cancer Biol. Ther. 7 2008 364 373
47. T.H. Tsai, C.H. Lee, and P.H. Yeh Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis Br. J. Pharmacol. 134 2001 1245 1252
48. S. Yang, J. Zhu, Y. Lu, B. Liang, and C. Yang Body distribution of camptothecin solid lipid nanoparticles after oral administration Pharm. Res. 16 1999 751 757
49. S.C. Yang, L.I. Lu, Y. Caic, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Controlled Release 59 1999 299 307
50. S.M. Martins, B. Sarmento, C. Nunes, M. Lúcio, S. Reis, and D.C. Ferreira Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration Eur. J. Pharm. Biopharm. 85 2013 488 502
51. S. Martins, I. Tho, I. Reimold, G. Fricker, E. Souto, D. Ferreira, and M. Brandl Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies Int. J. Pharm. 439 2012 49 62
52. K. Manjunath, and V. Venkateswarlu Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration J. Controlled Release 107 2005 215 228
53. G.R. Spratto, A.L. Woods, Delmar Nurse's Drug Handbook, 2009.
54. J.-X. Wang, X. Sun, and Z.-R. Zhang Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles Eur. J. Pharm. Biopharm. 54 2002 285 290
55. J. Madan, R.S. Pandey, V. Jain, O.M. Katare, R. Chandra, and A. Katyal Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells Nanomed.: Nanotechnol., Biol. Med. 9 2013 492 503
56. S.H. Buhner Herbal Antibiotics: Natural Alternatives for Treating Drug-resistant Bacteria 2012 Storey Publishing
57. M. Yusuf, M. Khan, R.A. Khan, and B. Ahmed Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model J. Drug Target. 21 2013 300 311
58. E. Esposito, M. Fantin, M. Marti, M. Drechsler, L. Paccamiccio, P. Mariani, E. Sivieri, F. Lain, E. Menegatti, M. Morari, and R. Cortesi Solid lipid nanoparticles as delivery systems for bromocriptine Pharm. Res. 25 2008 1521 1530
59. G. Huang, N. Zhanga, X. Bia, and M. Doub Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity Int. J. Pharm. 355 2008 314 320
60. C.J. Maxwell, D.B. Hogan, and E.M. Ebly Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging Can. Med. Assoc. J. 161 1999 501 506
61. S. Uchida, S. Yamada, K. Nagai, Y. Deguchi, and R. Kimura Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists Life Sci. 61 1997 2083 2090
62. K. Manjunath, and V. Venkateshwarlu Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration J. Drug Target. 14 2006 632 645
63. A.E.-H. de Mendoza, M.A. Campanero, J. de la Iglesia-Vicente, C. Gajate, F. Mollinedo, and M.J. Blanco-Prieto Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice Clin. Cancer Res. 15 2009 858 864
64. A. Nagler, Edelfosine for the Treatment of Brain Tumours, U.S. Patent 6514519 B1, 2003.
65. E.H.A. de Mendoza, V. Préat, F. Mollinedo, and M.J. Blanco-Prieto In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma J. Controlled Release 156 2011 421 426
66. S. Dhawan, R. Kapil, and B. Singh Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery J. Pharm. Pharmacol. 63 2011 342 351
67. L. Liu, Y. Tang, C. Gao, Y. Li, S. Chen, T. Xiong, J. Li, M. Du, Z. Gong, H. Chen, L. Liu, and P. Yao Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers Colloids Surf., B: Biointerfaces 115 2014 125 131
68. W. Gang, W.J. Jie, Z.L. Ping, D.S. Ming, L.J. Ying, W. Lei, and Y. Fang Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo Expert Opin. Drug Deliv. 9 2012 599 613
69. J.B. van Bree, C.D. Heijligers-Feijen, A.G. de Boer, M. Danhof, and D.D. Breimer Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology Pharm. Res. 8 1991 259 262
70. M.K. Shellenberger, L. Groves, J. Shah, and G.D. Novack A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state Drug Metab. Dispos. 27 1999 201 204
71. L. Priano, G.P. Zara, N. El-Assawy, S. Cattaldo, E. Muntoni, E. Milano, L. Serpe, C. Musicanti, C. Pérot, M.R. Gasco, G. Miscio, and A. Mauro Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration Eur. J. Pharm. Biopharm. 79 2011 135 141
72. G.P. Zara, R. Cavalli, A. Fundarò, A. Bargoni, O. Caputo, and M.R. Gasco Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres pharmacological research Pharmacol. Res. 40 1999 281 286
73. A. Fundarò, R. Cavalli, A. Bargoni, D. Vighetto, G.P. Zara, and M.R. Gasco Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats Pharmacol. Res. 42 2000 337 343
74. G.P. Zara, R. Cavalli, and A. Bargoni Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues J. Drug Target. 10 2002 327 335
75. A. Bargoni, R. Cavalli, G.P. Zara, A. Fundarò, O. Caputo, and M.R. Gasco Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - Tissue distribution Pharmacol. Res. 43 2001 497 502
76. G.P. Zara, A. Bargoni, R. Cavalli, A. Fundarò, D. Vighetto, and M.R. Gasco Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats J. Pharm. Sci. 91 2002 1324 1333
77. L.H. Reddy, R.K. Sharmab, K. Chuttanib, A.K. Mishrab, and R.S.R. Murthya Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice J. Controlled Release 105 2005 185 198
78. E. Peira, P. Marzola, V. Podio, S. Aime, A. Sbarbati, and M.R. Gasco In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide J. Drug Target. 11 2003 19 24
79. M.L. Bondi, E.F. Craparo, G. Giammona, and F. Drago Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution Nanomed.: Nanotechnol. Biol. Med. 5 2010 25 32
80. Y. Gao, W. Gu, L. Chen, Z. Xu, and Y. Li The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases Biomaterials 29 2008 4129 4136
81. J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper In situ blood-brain barrier transport of nanoparticles Pharm. Res. 20 2003 1772 1778
82. J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper Paclitaxel nanoparticles for the potential treatment of brain tumors J. Controlled Release 99 2004 259 269
83. P.R. Lockman, J. Koziara, K.E. Roder, J. Paulson, T.J. Abbruscato, R.J. Mumper, and D.D. Allen In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles Pharm. Res. 20 2003 705 713
84. N. Chattopadhyay, J. Zastre, H.L. Wong, X.W. Wu, and R. Bendayan Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line Pharm. Res. 25 2008 2262 2271
85. Y. Gupta, A. Jain, and S.K. Jain Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain J. Pharm. Pharmacol. 59 2007 935 940
86. H. Hatakeyama, H. Akita, K. Maruyama, T. Suhara, and Hideyoshi Harashima Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo Int. J. Pharm. 281 2004 25 33
87. C.C. Visser, S. Stevanović, L.H. Voorwinden, P.J. Gaillard, D.J.A. Crommelin, M. Danhof, and A.G. de Boer Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro J. Drug Target. 12 2004 145 150
88. V. Soni, D.V. Kohli, and S.K. Jain Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil J. Drug Target. 13 2005 245 250
89. J. Franco-Pérez, and C. Paz Quinine, a selective gap junction blocker, decreases REM sleep in rats Pharmacol. Biochem. Behav. 94 2009 250 254
90. V.K. Venishetty, R. Samala, R. Komuravelli, M. Kuncha, R. Sistla, and P.V. Diwan β-hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain Nanomed.: Nanotechnol. Biol. Med. 9 2013 388 397
91. V.K. Venishetty, R. Komuravelli, M. Kuncha, R. Sistla, and P.V. Diwan Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles Nanomed.: Nanotechnol. Biol. Med. 9 2013 111 121
92. C. Gao, X. Li, Y. Li, L. Wang, and M. Xue Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats J. Pharm. Pharmacol. 62 2010 360 367
93. J. Ren, M. Zou, P. Gao, Y. Wang, and G. Cheng Tissue distribution of borneol-modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration Eur. J. Pharm. Biopharm. 83 2013 141 148
94. Y.-C. Kuo, and H.-F. Ko Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles Biomaterials 34 2013 4818 4830
95. D.D. Allen, P.R. Lockman, M.O. Oyewumi, J.M. Koziara, K.E. Roder, and R.J. Mumper Brain uptake of thiamine-coated nanoparticles J. Controlled Release 93 2003 271 282
96. T.M. Goppert, and R.H. Muller Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns J. Drug Target. 13 2005 179 187
97. P. Blasi, S. Giovagnoli, A. Schoubben, C. Puglia, F. Bonina, C. Rossi, and M. Ricci Lipid nanoparticles for brain targeting I. Formulation optimization Int. J. Pharm. 419 2011 287 295
98. P. Blasi, A. Schoubben, G.V. Romano, S. Giovagnoli, A. Di Michele, and M. Ricci Lipid nanoparticles for brain targeting II. Technological charaterization Colloids Surf. B: Biointerfaces 110 2013 130 137
99. V. Kakkar, A.K. Mishra, K. Chuttani, and I.P. Kaur Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain Int. J. Pharm. 448 2013 354 359
100. V. Kakkar, and I.P. Kaur Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain Food Chem. Toxicol. 49 2011 2906 2913
101. V. Kakkar, and I.P. Kaur Antidepressant activity of curcumin loaded solid lipid nanoparticles (C-SLNs) in mice Am. J. PharmTech Res. 2 2012 729 736
102. J. Jin, K.H. Bae, H. Yang, S.J. Lee, H. Kim, Y. Kim, K.M. Joo, S.W. Seo, T.G. Park, and D.-H. Nam In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles Bioconjug. Chem. 22 2011 2568 2572
103. A. Agarwal, S. Majumder, H. Agrawal, S. Majumdar, and G.P. Agrawal Cationized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug Curr. Nanosci. 7 2011 71 80
104. Y.C. Kuo, and C.C. Wang Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia Colloids Surf., B: Biointerfaces 101 2013 101 105